Pharming Group N.V annual cash and equivalents
2018
2019
2020
2021
2022
2023
2024
2025
Pharming Group N.V Cash & Equivalents Growth & History (PHAR)
Pharming Group N.V's cash and equivalents was $145.3M for fiscal 2025.
View full Pharming Group N.V company overviewPharming Group N.V annual cash and equivalents history
| Fiscal year | Period ended | Cash and equivalents | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $145.3M | $90.4M | +164.46% |
| 2024 | 2024-12-31 | $54.9M | −$6.8M | −11.01% |
| 2023 | 2023-12-31 | $61.7M | −$145.6M | −70.22% |
| 2022 | 2022-12-31 | $207.3M | $15.4M | +8.03% |
| 2021 | 2021-12-31 | $191.9M | −$13.2M | −6.45% |
| 2020 | 2020-12-31 | $205.2M | $130.8M | +175.94% |
| 2019 | 2019-12-31 | $74.3M | −$17.5M | −19.07% |
| 2018 | 2018-12-31 | $91.9M | — | — |
Pharming Group N.V quarterly cash and equivalents
Q4.21
Q4.22
Q4.23
Q4.24
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Cash and equivalents | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $158.3M | $66.2M | +71.87% |
| Q1 2026 | 2026-03-31 | $52.4M | — | — |
| Q4 2025 | 2025-12-31 | $145.3M | $90.4M | +164.46% |
| Q3 2025 | 2025-09-30 | $132.4M | — | — |
| Q2 2025 | 2025-06-30 | $92.1M | — | — |
| Q4 2024 | 2024-12-31 | $54.9M | −$6.8M | −11.01% |
| Q4 2023 | 2023-12-31 | $61.7M | −$145.6M | −70.22% |
| Q4 2022 | 2022-12-31 | $207.3M | $15.4M | +8.03% |
| Q4 2021 | 2021-12-31 | $191.9M | — | — |
Pharming Group N.V cash and equivalents trends
Over the last five fiscal years, Pharming Group N.V's cash and equivalents decreased from $205.2M to $145.3M, a change of −$59.9M. The latest reported quarter, Q2 2026, shows $158.3M.
About the metric
What cash and equivalents mean
Cash and cash equivalents, often described as cash on hand, are highly liquid resources available for near-term obligations, investment, acquisitions, debt repayment, dividends, or share repurchases. This measure does not include short-term investments reported separately.
Calculation and source
Reported cash and equivalents
TickerStat standardizes cash and cash equivalents reported on the balance sheet. Restricted cash is included only when the company reports it within the selected consolidated cash concept. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Pharming Group N.V source filings ↗Community posts
Pharming expands Joenja approval to younger children with APDS
Pharming ($PHAR) secured FDA approval to use Joenja in children aged four to 11 with activated PI3K delta syndrome who weigh at least 27 kilograms. The expansion adds younger patients to the medicine’s existing indication for older patients ...